News
Jobs
Career Advice
Companies
Hotbeds
More

SUBSCRIBE

SUBSCRIBE

News
Jobs
Career Advice
Companies
Hotbeds
More

Search Query

Search Results

85,757 Results

Type

Article (2880)
Company Profile (21)
Press Release (82856)

Section

Business (38390)
Career Advice (52)
Deals (5946)
Drug Delivery (9)
Drug Development (11489)
Employer Resources (7)
FDA (2054)
Job Trends (2353)
News (55636)
Policy (3415)

Tag

Date

Today (1)
Last 7 days (67)
Last 30 days (225)
Last 365 days (6686)
2024 (3604)
2023 (6915)
2022 (8318)
2021 (8139)
2020 (8155)
2019 (6925)
2018 (5075)
2017 (4621)
2016 (3831)
2015 (4361)
2014 (3190)
2013 (2086)
2012 (2497)
2011 (2731)
2010 (2789)

Filters

Type

Article (2880)
Company Profile (21)
Press Release (82856)

Section

Business (38390)
Career Advice (52)
Deals (5946)
Drug Delivery (9)
Drug Development (11489)
Employer Resources (7)
FDA (2054)
Job Trends (2353)
News (55636)
Policy (3415)

Tag

Date

Today (1)
Last 7 days (67)
Last 30 days (225)
Last 365 days (6686)
2024 (3604)
2023 (6915)
2022 (8318)
2021 (8139)
2020 (8155)
2019 (6925)
2018 (5075)
2017 (4621)
2016 (3831)
2015 (4361)
2014 (3190)
2013 (2086)
2012 (2497)
2011 (2731)
2010 (2789)

85,757 Results for "32".

Sort By

Press Releases

Q32 Bio Joins Russell 3000® Index

Q32 Bio Inc. today announced that the company is joining the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell Indexes annual reconstitution, effective upon the U.S. market opening today, July 1, 2024.

July 1, 2024
·
6 min read
Business

Lilly Pays $3.2B to Buy Morphic and Deepen Immunology, Gastro Portfolio

Eli Lilly on Monday announced a $3.2 billion all-cash deal to purchase Morphic and its pipeline of oral integrin therapies in a move to expand the pharma’s presence in the autoimmune diseases space.

July 8, 2024
·
2 min read
·
Tristan Manalac
Deals

Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split - June 6, 2024

Tonix Pharmaceuticals Holding Corp. today announced that it will effect a 1-for-32 reverse stock split of its outstanding common stock.

June 6, 2024
·
4 min read
BioMidwest

SciTech Development Raises Additional $3.2M to Expand Clinical Trials for Cancer

SciTech Development, a clinical-stage, specialty oncology pharmaceutical company, today announced it has closed an additional $3.2 million in funding to continue the active enrollment and dosing of patients in its ongoing clinical trial for T-cell non-Hodgkin lymphoma (T-NHL).

June 4, 2024
·
5 min read
Cell Expansion Market Experiencing Rapid Growth 12.32% by 2032

The global cell expansion market size was evaluated at US$ 17.61 billion in 2023 and is expected to attain around US$ 56.16 billion by 2033, growing at a CAGR of 12.32% from 2024 to 2033

April 30, 2024
·
11 min read
Genetown

BioBam Releases OmicsBox 3.2: Single Cell Transcriptomics Made Easy

BioBam, a leading provider of bioinformatics solutions, is pleased to announce the launch of OmicsBox 3.2 at the BIO-IT World Expo in Boston.

April 15, 2024
·
4 min read
Business

Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Inc., a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, reported financial results for the quarter ended March 31, 2024 and provided recent corporate updates.

May 9, 2024
·
11 min read
Scryb Applauds New Bipartisan $32B Roadmap for AI Policy from U.S. Senate; Driving the Market for Scryb’s AI Compliance Solution

Scryb Inc. (CSE: SCYB) (OTC Pink: SCYRF) (FSE: EIY) (Scryb’’ or the “Company”) is pleased to share that after several months of anticipation the U.S. Senate has released a $32 Billion “Bipartisan Roadmap for AI Policy’’

June 3, 2024
·
5 min read
Business

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

Q32 Bio Inc., a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, announced the appointment of Lee Kalowski as President and Chief Financial Officer.

April 3, 2024
·
6 min read
Deals

Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million

Q32 Bio Inc. (NASDAQ: QTTB) (“Q32 Bio”), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced the completion of its previously announced merger with Homology Medicines, Inc. (“Homology”).

March 25, 2024
·
9 min read

1 of 8,576

BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.

Explore
Hotbeds
About
More

© 1985 - 2024 BioSpace.com. All rights reserved.

twitter
instagram
facebook
linkedin